Linking product development outcomes to market valuation of the firm: The case of the U.S. pharmaceutical industry

Journal of Product Innovation Management

Volumn 21, Issue 5, 2004, Pages 297-308

  Sharma, Anurag ^a   Lacey, Nelson ^a  

^a UNIVERSITY OF MASSACHUSETTS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FINANCIAL MARKET; FOOD AND DRUG ADMINISTRATION (FDA); PHARMACEUTICAL INDUSTRY; PRODUCT INNOVATION;

COMPETITION; FINANCE; MARKETING; PRODUCT DEVELOPMENT; RISK ASSESSMENT; SUSTAINABLE DEVELOPMENT;

DRUG PRODUCTS PLANTS;

EID: 4344660218     PISSN: 07376782     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.0737-6782.2004.00084.x     Document Type: Conference Paper

References (58)

1. Ahorony, Joseph and Swary, Iizhak (1980). Quarterly Dividend and Earnings Announcements and Stockholders' Return: An Empirical Analysis. Journal of Finance 35(1): 1-12.
2. Anand, Bahrat N. and Khanna, Tarun (2000). Do Firms Learn to Create Value? The Case of Alliances. Strategic Management Journal 21(3):295-315.
3. Anderson, N.H. (1981). Foundations of Information Integration Theory. New York: Academic Press.
4. Arndt, Johan (1967). Role of Product-Related Conversations in the Diffusion of New Product. Journal of Marketing Research 4(3): 196-291.
5. Barney, Jay (1995). Looking Inside for Competitive Advantage. Academy Of Management Executive 9(4):49-61.
6. Basu, S. (1977). Investment Performance of Common Stocks in Relation to the Price-Earnings Ratio: A Test of the Efficient Market Hypothesis. Journal of Finance 32(3):663-682.
7. Bierly, Paul and Chakrabarti, Alok (1996). Generic Knowledge Strategies in the U.S. Pharmaceutical Industry. Strategic Management Journal 17 (Special Issue): 123-135.
8. Brown, Shona L. and Eisenhardt, Kathleen M. (1995). Product Development: Past Research, Present Findings, and Future Directions. Academy of Management Review 20(2):343-378.
9. Brown, Stephen J. and Warner, Jerold B. (1980). Measuring Security Price Information. Journal of Financial Economics 8(3):205-258.
10. Brown, Stephen J. and Warner, Jerold B. (1985). Using Daily Stock Returns: The Case of Event Studies. Journal of Financial Economics 14(1):3-31.
11. Chaney, Paul K., Devinney, Timothy M. and Winer, Russel S. (1991). The Impact of New Product Introductions on the Market Value of Firms. Journal of Business 64(4):573-610.
12. Cooper, Robert G. and Kleinschmidt, Elko J. (1987). New Products: What Separates Winners from Losers? Journal of Product Innovation Management 4(3):169-185.
13. Cordero, Rene (1991). Managing for Speed to Avoid Product Obsolescence: A Survey of Techniques. Journal of Product Innovation Management 8(4):283-294.
14. DiMasi, Joseph A. (2001). New Drug Development in the United States, 1963-1999. Clinical Pharmacology and Therapeutics 69(5):69-78.
15. Dos Santos, Brian L. and Peffers, Ken (1995). Rewards to Investors in Innovative Information Technology Applications: First Movers and Early Followers in ATMs. Organization Science 6(3): 241-260.
16. Eddy, Albert R. and Saunders, George B. (1980). New Product Announcements and Stock Prices. Decision sciences 11(1):90-97.
17. Fama, Eugene F. (1991). Efficient Capital Markets II. Journal of Finance 46(5):1575-1618.
18. Fama, Eugene, Fisher, L., Jensen, Michael and Roll, Richard (1969). The Adjustment of Stock Price to New Information. International Economic Review 10(1):1-21.
19. Fiske, Susan T. (1980). Attention and Weight in Person Perception: The Impact of Negative and Extreme Behavior. Journal of Personality and Social Psychology 38(6):889-906.
20. Geroski, Paul, Machin, Stephen and Van Reenen, John (1993). The Profitability of Innovating Firms. Rand Journal of Economics 24(2): 198-211.
21. Gopalakrishnan, Shanthi and Damanpour, Fairborz (2000). IEEE Transactions on Engineering Management 47(1): 14-25.
22. Grabowski, Henry, Vernon, John and DiMasi, Joseph (2002). Returns on Research and Development for the 1990s New Drug Introductions. Pharmacoeconomics 20(3):11-29.
23. Grabowski, Henry and Vernon, Joseph (1992). Brand Loyalty, Entry, and Price Competition in Pharmaceuticals after the 1984 Drug Act. Journal of Law and Economics 35(2):331-351.
24. Griffin, Abbie (1997). PDMA Research on New Product Development Practices: Updating Trends and Benchmarking Best practices. Journal of Product Innovation Management 14(6):429-458.
25. Griffin, Abbie and Page, Albert L. (1996). PDMA Success Measurement Project: Recommended Measures for Product Development Success and Failure. Journal of Product Innovation Management 13(6):478-496.
26. Gupta, Ashok K. and Wileman, David L. (1990). Accelerating the Development of Technology-Based New Products. California Management Review 32(2):24-44.
27. Helson, Harry (1964). Adaptation-Level Theory. New York: Harper.
28. Henderson, Rebecca and Cockburn, lain (1994). Measuring Competence? Exploring Firm Effects in the Pharmaceutical Research. Strategic Management Journal 15(Special Issue):63-84 (Winter).
29. Hillman, Amy J. and Keim, Gerald D. (2001). Shareholder Value, Stakeholder Management, and Social Issues: What's the Bottom Line? Strategic Management Journal 22(2): 125-140.
30. Jacobson, Robert (1988). The Persistence of Abnormal Returns. Strategic Management Journal 9(5):415-430.
31. Kanouse, David E. and Hanson, L.R. (1972). Negativity in Evaluations. New York: General Learning Press.
32. Langowitz, Nan S. and Graves, Samuel B. (1992). Innovative Productivity in Pharmaceutical Firms. Research Technology Management 35(2):39-42.
33. Lieberman, Marvin B. and Montgomery, David B. (1988). First-Mover Advantages. Strategic Management Journal 9(12):41-59.
34. Lieberman, Marvin B. and Montgomery, David B. (1998). First-Mover (Dis)advantages: Retrospective and Link with the Resource-Based View. Strategic Management Journal 19(12):1111.
35. Mabert, Vincent A., Muth, John F. and Schmenner, Roger W. (1992). Collapsing New Product Development Times: Six Case Studies. Journal of Product Innovation Management 9(3):200-212.
36. Markides, Constantinos C. and Ittner, Christopher D. (1994). Shareholder Benefits from Corporate International Diversification: Evidence from US International Acquisitions. Journal of International Business Studies 25(2):343-367.
37. McConnell, John J. and Nantell, Timothy J. (1985). Corporate Combinations and Common Stock Returns: The Case of Joint Ventures. Journal of Finance 40(2):519-537.
38. Mizerski, Richard (1982). An Attribution Explanation of Disproportionate Influence of Unfavorable Information. Journal of Consumer Research 9(3):301-310.
39. Mueller, Dennis (1987). Profits in the Long Run. Rand Journal of Economics 18(2):319-353.
40. McConnell, John and Muscarella, Chris (1985). Corporate Capital Expenditure Decisions and the Market Value of the Firm. Journal of Financial Economics 14(3):399-422.
41. Neergaard, Lauran (2001), No Slowdown Seen in Drug OKs by FDA. Boston Globe, August 20, A1.
42. Pakes, Ariel (1970). On Patents, R&D, and the Stock Market Rate of Return. Journal of Political Economy 93(2):390-409.
43. Parducci, Allen (1968). The Relativism of Absolute Judgments. Scientific American 219:84-90.
44. Rendleman, Richard J., Jones, Charles P. and Latane, Henry A. (1982). Empirical Anomalies Based on Unexpected Earnings and the Importance of Risk Adjustments. Journal of Financial Economics 10(3):269-287.
45. Roberts, Peter W. (1999). Product Innovation, Product-Market Competition, and Persistent Profitability in the U.S. Pharmaceutical Industry. Strategic Management Journal 20(7):655-670.
46. Shleifer, Andrei (2000). Inefficient Markets: An Introduction to Behavioral Finance. New York: Oxford University Press.
47. Schumpeter, Joseph (1934). The Theory of Economic Development. Cambridge, MA: Harvard University Press.
48. Seth, Anju (1990). Value Creation in Acquisitions: A Reexamination of Performance Issues. Strategic Management Journal 11(2): 99-115.
49. Sherif, Muzafer and Sherif, Carolyn W. (1967). Attitudes as Individuals' Own Categories: The Social Judgment Approach to Attitude Change. In: Attitude, Ego Involvement, and Change. C.W. Sherif and M. Sherif (eds.). New York: Wiley, 105-139.
50. Skinner, Douglas J. (1994). Why Firms Voluntarily Disclose Bad News. Journal of Accounting Research 32(1):38-60.
51. Skowronski, John J. and Carlston, Donal E. (1989). Negativity and Extremity in Impression Formation: A Review of Explanations. Psychological Bulletin 105(1):131-142.
52. Teece, David J. (1986). Profiting from Technological Innovation: Implications for Integration, Collaboration, Licensing and Public Policy. Research Policy 15(6):285-305.
53. Weinberger, Marc G. and Romeo, Jean B. (1989). The Impact of Negative Product News. Business Horizons 32(1):44-50.
54. Weinberger, Marc G. and Lepkowska-White (2000). The Influence of Negative Information on Purchase Behavior. Journal of Marketing Management 16:465-482.
55. Wernerfeit, Birger and Karnani, Aneel (1987). Competitive Strategy under Uncertainty. Strategic Management Journal 8(2): 187-195.
56. Woolridge, Randall J. and Snow, Charles C. (1990). Stock Market Reaction to Strategic Investment Decisions. Strategic Management Journal 11(5):353-363.
57. Yeoh, Poh-Lin and Roth, Kendall (1999). An Empirical Analysis of Sustained Advantage in the U.S. Pharmaceutical Industry: Impact of Firm Resources and Capabilities. Strategic Management Journal 20(7):637-653.
58. Zirger, Billie Jo and Maidique, Modesto A. (1990). A Model of New Product Development: An Empirical Test. Management Science 36(7):867-883.